Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04410523 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 335
- Enrollment target
NCT04410523 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 335 participants.
The verdict
NCT04410523, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 335 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and safety of multiple CSJ117 doses (0.5; 1; 2; 4 and 8 mg) inhaled once daily compared with placebo, when added to standard-of-care (SoC) asthma therapy in adult patients with uncontrolled asthma with respect to change from baseline in FEV1 at the end of 12 weeks of treatment.
Interventions
- DRUG Placebo
- DRUG CSJ117
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 335 participants |
| Start Date | 2020-09-09 |
| Est. Completion | 2022-09-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04410523
The ClinicalTrials.gov registry entry for NCT04410523 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 335 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04410523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04410523 about?
NCT04410523 is a clinical study titled "Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma". The purpose of this study is to determine the efficacy and safety of multiple CSJ117 doses (0.5; 1; 2; 4 and 8 mg) inhaled once daily compared with placebo, when added to standard-of-care (SoC) asthma therapy in adult patients with uncontrolled asthma with respect to change from baseline in FEV1 at ...
What is the current status of trial NCT04410523?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 335 participants. The study started on 2020-09-09. Estimated completion is 2022-09-06.
What interventions are being tested in trial NCT04410523?
The interventions under investigation include: Placebo (DRUG), CSJ117 (DRUG).
Who is sponsoring clinical trial NCT04410523?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.